



OUR PIPELINE OVERVIEW

Boehringer Ingelheim is taking on cancer through a dedicated commitment to delivering first-in-class cancer-cell directed therapies, innovative immuno-oncology strategies and smart combination approaches. Our goal is to achieve cancer breakthroughs that give hope to patients. Find out more about our oncology clinical trial program and long-term research commitment.

COMPOUND AND TARGET	LATEST DEVELOPMENT PHASE (AS OF JULY 2021)		
	Phase I	Phase II	Phase III
Cancer cell-directed and immuno-oncology therapies			
Xentuzumab (BI 836845)	Breast cancer ^{1,2}	Breast cancer ³	
VEGF/Ang2 inhibitor (BI 836880)	Solid tumors ⁴⁻⁶		
Ezabenlimab (BI 754091)	Solid tumors ⁷		
MDM2-p53 antagonist (BI 907828)	Solid tumors ⁸		
LRP5/6 antagonist (BI 905677)	Solid tumors ⁹		
SIRPα antagonist (BI 765063)	Solid tumors ¹⁰		
SOS1::KRAS inhibitor (BI 1701963)	Solid tumors ¹¹		
	CRC ¹²		
TRAILR2/CDH17 antibody (BI 905711)	Gastrointestinal cancers ¹³		
STING agonist (BI 1387466)	Solid tumors ¹⁴		
KISIMA™ cancer vaccine (ATP-128)	CRC ¹⁵		
DLL3/CD3 bispecific antibody (BI 764532)	SCLC ¹⁶		
	NETs ¹⁶		
MEK inhibitor (BI 3011441)	Solid tumors ¹⁷		
ROR1 ADC	Solid tumors ¹⁸		
B7-H6/CD3 antibody (BI 765049)	Solid tumors ¹⁹		
HER2 exon 20 inhibitor (BI 1810631)	Solid tumors ²⁰		
KRAS G12C inhibitor (in preparation)			
CD137/FAP bispecific agonist antibody (in preparation)			
VSV-GP oncolytic virus platform (in preparation)			

Continued on next page



OUR PIPELINE OVERVIEW

COMPOUND AND TARGET	LATEST DEVELOPMENT PHASE (AS OF JULY 2021)		
	Phase I	Phase II	Phase III
Combination approaches			
VEGF/Ang2 inhibitor (BI 836880) + ezabenzimab (BI 754091)	NSCLC ²¹	Gastrointestinal cancers ²²	
	Solid tumors ^{6,21}	Solid tumors ²²	
SIRPα antagonist (BI 765063) + ezabenzimab (BI 754091)	Solid tumors ¹⁰		
STING agonist (BI 1387446) + ezabenzimab (BI 754091)	Solid tumors ¹⁴		
DLL3/CD3 bispecific antibody (BI 764532) + ezabenzimab (BI 754091)	SCLC ¹⁶		
	NETs ¹⁶		
KISIMA™ cancer vaccine (ATP-128) + ezabenzimab (BI 754091)	CRC ¹⁵		
SOS1::KRAS inhibitor (BI 1701963) + MAPK pathway inhibitor (trametinib)	Solid tumors ¹¹		
SOS1::KRAS inhibitor (BI 1701963) + irinotecan	CRC ¹²		
MDM2-p53 antagonist (BI 907828) + ezabenzimab (BI 754091)	Solid tumors ²³		
B7-H6/CD3 antibody (BI 765049) + ezabenzimab (BI 754091)	Solid tumors ¹⁹		
MEK inhibitor (BI 3011441) + SOS1::KRAS inhibitor (BI 1701963)	Solid tumors ²⁴		

Pipeline compounds shown here are under pre-clinical and/or clinical investigation, and have not been approved. Their safety and efficacy have not been established.

ADC, antibody-drug conjugate; Ang2, angiopoietin 2; CD, cluster of differentiation; CDH17, cell anchor cadherin 17; CRC, colorectal cancer; DLL3, Delta-like 3; EGFR, epidermal growth factor receptor; FAP, fibroblast activation protein; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma; LRP, lipoprotein receptor-related protein; MDM2, murine double minute 2 protein; MEK, mitogen-activated extracellular signal regulated kinase; NSCLC, non-small-cell lung cancer; NET, neuroendocrine tumor; ROR1, receptor tyrosine kinase-like orphan receptor 1; SCLC, small-cell lung cancer; SIRPα, signal-regulatory protein alpha; SOS1, Son of sevenless homolog 1; STING, small molecule agonist of the stimulator of interferon genes; TRAILR2, tumor necrosis factor-related apoptosis-inducing ligand receptor 2; VEGF, vascular endothelial growth factor; VSV, vesicular stomatitis virus.

References: 1. ClinicalTrials.gov. NCT03099174. <https://clinicaltrials.gov/ct2/show/NCT03099174> (Accessed: July 2021); 2. ClinicalTrials.gov. NCT02123823. <https://clinicaltrials.gov/ct2/show/NCT02123823> (Accessed: July 2021); 3. ClinicalTrials.gov. NCT03659136. <https://clinicaltrials.gov/ct2/show/NCT03659136> (Accessed: July 2021); 4. ClinicalTrials.gov. NCT02674152. <https://clinicaltrials.gov/ct2/show/NCT02674152> (Accessed: July 2021); 5. ClinicalTrials.gov. NCT02689505. <https://clinicaltrials.gov/ct2/show/NCT02689505> (Accessed: July 2021); 6. ClinicalTrials.gov. NCT03972150. <https://clinicaltrials.gov/ct2/show/NCT03972150> (Accessed: July 2021); 7. ClinicalTrials.gov. NCT02952248. <http://clinicaltrials.gov/ct2/show/NCT02952248> (Accessed: July 2021); 8. ClinicalTrials.gov. NCT03449381. <https://clinicaltrials.gov/ct2/show/NCT03449381> (Accessed: July 2021); 9. ClinicalTrials.gov. NCT03604445. <https://clinicaltrials.gov/ct2/show/NCT03604445> (Accessed: July 2021); 10. ClinicalTrials.gov. NCT03990233. <https://clinicaltrials.gov/ct2/show/NCT03990233> (Accessed: July 2021); 11. ClinicalTrials.gov. NCT04111458. <https://clinicaltrials.gov/ct2/show/NCT04111458> (Accessed: July 2021); 12. ClinicalTrials.gov. NCT04627142. <https://clinicaltrials.gov/ct2/show/NCT04627142> (Accessed: July 2021); 13. ClinicalTrials.gov. NCT04137289. <https://clinicaltrials.gov/ct2/show/NCT04137289> (Accessed: July 2021); 14. ClinicalTrials.gov. NCT04147234. <https://clinicaltrials.gov/ct2/show/NCT04147234> (Accessed: July 2021); 15. ClinicalTrials.gov. NCT04046445. <https://clinicaltrials.gov/ct2/show/NCT04046445> (Accessed: July 2021); 16. ClinicalTrials.gov. NCT04429087. <https://clinicaltrials.gov/ct2/show/NCT04429087> (Accessed: July 2021); 17. ClinicalTrials.gov. NCT04742556. <http://clinicaltrials.gov/ct2/show/NCT04742556> (Accessed: July 2021); 18. ClinicalTrials.gov. NCT04441099. <http://clinicaltrials.gov/ct2/show/NCT04441099> (Accessed: July 2021); 19. ClinicalTrials.gov. NCT04752215. <https://clinicaltrials.gov/ct2/show/NCT04752215> (Accessed: July 2021); 20. ClinicalTrials.gov. NCT04886804. <https://clinicaltrials.gov/ct2/show/NCT04886804> (Accessed: July 2021); 21. ClinicalTrials.gov. NCT03468426. <https://clinicaltrials.gov/ct2/show/NCT03468426> (Accessed: July 2021); 22. ClinicalTrials.gov. NCT03697304. <https://clinicaltrials.gov/ct2/show/NCT03697304> (Accessed: July 2021); 23. ClinicalTrials.gov. NCT03964233. <https://clinicaltrials.gov/ct2/show/NCT03964233> (Accessed: July 2021); 24. ClinicalTrials.gov. NCT04835714. <https://clinicaltrials.gov/ct2/show/NCT04835714> (Accessed: July 2021).

© 2021 Boehringer Ingelheim International GmbH. This document and its contents are the property of Boehringer Ingelheim (third party sources are indicated) and are, inter alia, protected by copyright law. Complete or partial passing on to third parties, as well as copying, reproduction, publication or any other use by third parties, is not permitted.